Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 42%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is well-positioned as a leading pharmaceutical company with a strong portfolio including Keytruda and Gardasil, and a promising pipeline that includes potential blockbuster drugs such as Islatravir + Lenacapavir for HIV and enlicitide for PCSK9 inhibition. The upcoming catalysts, such as data readouts from Trop-2 sac-TMT and Phase 3 trials for tulisokibart, provide potential for further upside. The company also has a strong presence in the pediatric vaccine market and animal health industry, diversifying its revenue streams.

Bears say

Merck & Co is facing potential challenges in its revenue growth due to several factors, including a negative outlook on Keytruda, potential product failure in clinical trials, and risks related to generic or biosimilar competition. The company's recent acquisition of Terns Pharma may also have a negative impact in the short term, as reflected in its 2Q earnings with a $5.8B charge. However, the company has a strong portfolio of products in various therapeutic areas and may have potential for growth in the future, though this growth may be underappreciated by investors. The company also faces risks related to macroeconomic conditions and potential delays or rejections for approval of investigational assets.

Merck (MRK) has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 42% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 19 analysts, Merck (MRK) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $131.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $131.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.